ONVO Key Statistics, Chart & Performance
The current stock price of ONVO is 2.04 USD. In the past month the price decreased by -28.17%. In the past year, price decreased by -83%.
ONVO Technical Analysis
ONVO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONVO. The financial health of ONVO is average, but there are quite some concerns on its profitability.
ONVO Financial Highlights
Over the last trailing twelve months ONVO reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS increased by 60.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -322.19% | ||
| ROE | -3402.47% | ||
| Debt/Equity | 0 |
ONVO Forecast & Estimates
For the next year, analysts expect an EPS growth of 96.31% and a revenue growth 126.67% for ONVO
ONVO Ownership
ONVO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.21 | 393.136B | ||
| AMGN | AMGEN INC | 16.27 | 196.357B | ||
| GILD | GILEAD SCIENCES INC | 17.47 | 182.665B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 117.594B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 79.341B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.11 | 42.669B | ||
| INSM | INSMED INC | N/A | 31.681B | ||
| NTRA | NATERA INC | N/A | 29.21B | ||
| BIIB | BIOGEN INC | 12.57 | 27.736B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.15 | 20.376B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ONVO
Company Profile
Organovo Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. Organovo Holdings, Inc. is a clinical-stage biotechnology company. The firm is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The firm has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
Company Info
ORGANOVO HOLDINGS INC
Suite 100, 11555 Sorrento Valley Road
San Diego CALIFORNIA 92075 US
CEO: Keith Murphy
Employees: 20
Phone: 18582241000
ORGANOVO HOLDINGS INC / ONVO FAQ
What does ORGANOVO HOLDINGS INC do?
Organovo Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. Organovo Holdings, Inc. is a clinical-stage biotechnology company. The firm is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease (IBD). The firm has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
What is the stock price of ORGANOVO HOLDINGS INC today?
The current stock price of ONVO is 2.04 USD. The price increased by 1.49% in the last trading session.
Does ORGANOVO HOLDINGS INC pay dividends?
ONVO does not pay a dividend.
How is the ChartMill rating for ORGANOVO HOLDINGS INC?
ONVO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ONVO stock?
ORGANOVO HOLDINGS INC (ONVO) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for ONVO stock?
The Revenue of ORGANOVO HOLDINGS INC (ONVO) is expected to grow by 126.67% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does ORGANOVO HOLDINGS INC have?
ORGANOVO HOLDINGS INC (ONVO) currently has 20 employees.